Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
Add more filters










Database
Language
Publication year range
1.
Rev Assoc Med Bras (1992) ; 70(4): e20230998, 2024.
Article in English | MEDLINE | ID: mdl-38716936

ABSTRACT

OBJECTIVE: The use of cardiac implantable electronic devices has increased in recent years. It has also brought some issues. Among these, the complications of cardiac implantable electronic devices infection and pocket hematoma are difficult to manage. It can be fatal with the contribution of patient-related risk factors. In this study, we aimed to find mortality rates in patients who developed cardiac implantable electronic devices infection and pocket hematoma over 5 years. We also investigated the risk factors affecting mortality in patients with cardiac implantable electronic devices. METHODS: A total of 288 cardiac implantable electronic devices patients were evaluated. Demographic details, history, and clinical data of all patients were recorded. Cardiac implantable electronic devices infection was defined according to the modified Duke criteria. The national registry was used to ascertain the mortality status of the patients. The patients were divided into two groups (exitus and survival groups). In addition, the pocket hematoma was defined as significant bleeding at the pocket site after cardiac implantable electronic devices placement. RESULTS: The cardiac implantable electronic devices infection was similar in both groups (p=0.919), and the pocket hematoma was higher in the exitus group (p=0.019). The exitus group had higher usage of P2Y12 inhibitors (p≤0.001) and novel oral anticoagulants (p=0.031). The Cox regression analysis, including mortality-related factors, revealed that renal failure is the most significant risk factor for mortality. Renal failure was linked to a 2.78-fold higher risk of death. CONCLUSION: No correlation was observed between cardiac implantable electronic devices infection and mortality, whereas pocket hematoma was associated with mortality. Furthermore, renal failure was the cause of the highest mortality rate in patients with cardiac implantable electronic devices.


Subject(s)
Defibrillators, Implantable , Hematoma , Pacemaker, Artificial , Humans , Female , Male , Defibrillators, Implantable/adverse effects , Risk Factors , Aged , Middle Aged , Pacemaker, Artificial/adverse effects , Hematoma/etiology , Hematoma/mortality , Prosthesis-Related Infections/mortality , Prosthesis-Related Infections/etiology , Retrospective Studies , Time Factors , Aged, 80 and over
2.
Nutrients ; 15(19)2023 Sep 28.
Article in English | MEDLINE | ID: mdl-37836479

ABSTRACT

BACKGROUND: Atrial fibrillation (AF) is the most common rhythm disorder in the elderly. The AF can cause life-threatening thromboembolic complications. Therefore, there is a need to determine the risk factors of AF. In this study, we aimed to examine the association of markers of malnutrition with AF in individuals aged 75 years and older and to find the factors that may affect mortality. METHODS: In this prospective study, 358 consecutive individuals aged 75 years and older presenting to the cardiology outpatient clinic were included. All participants were divided into AF and sinus rhythm (SR) groups. In addition, a questionnaire and scoring system were used to assess malnutrition status. Information was obtained from all patients through outpatient clinic visits or telephone interviews for one year. Death from any cause was considered as the endpoint. RESULTS: AF was observed in 71 (19.8%) patients. Death was higher in patients with AF (p < 0.001), high CONUT score (p = 0.018), and GLIM malnutrition (p = 0.018). GLIM malnutrition caused a 2.8-fold increase in the development of AF. CONCLUSIONS: Screening for malnutrition in the elderly is essential. According to GLIM criteria, malnutrition may play a role in the development of AF and increase one-year mortality in the elderly.


Subject(s)
Atrial Fibrillation , Malnutrition , Aged , Humans , Atrial Fibrillation/complications , Atrial Fibrillation/epidemiology , Atrial Fibrillation/diagnosis , Prospective Studies , Malnutrition/complications , Malnutrition/epidemiology , Risk Factors
3.
Med Sci Monit ; 29: e941435, 2023 Aug 28.
Article in English | MEDLINE | ID: mdl-37635347

ABSTRACT

BACKGROUND Atrial fibrillation (AF) is one of the most common heart rhythm disorders. Identification and early treatment of AF risk factors can improve mortality and morbidity rates. This study aimed to compare the renal venous stasis index (RVSI) and intra-renal venous flow (IRVF) patterns evaluated by intra-renal Doppler ultrasonography in patients with AF and sinus rhythm (SR). MATERIAL AND METHODS A total of 68 patients, 34 with AF (lasting >12 months AF) and 34 with SR (no previous diagnosis of AF and no AF attack in 24-h Holter monitoring) were included in the study. The RVSI was calculated, and the IRVF patterns were determined using intra-renal Doppler ultrasonography. High RVSI was defined as >0.12 RVSI. In addition, echocardiography and a 6-min walk test were performed. A model including diabetes mellitus, hypertension, creatine, Pro-BNP, left ventricular ejection fraction, presence of AF, and systolic pulmonary artery pressure was created to evaluate the effects of variables on high RVSI. RESULTS The RVSI value was significantly higher in patients with AF than in those with SR (P=0.004). The SR group exhibited a higher prevalence of the continuous flow pattern, which is one of the IRVF patterns (P=0.015). In contrast, the biphasic flow pattern was observed more frequently in patients with AF (P=0.003). The presence of AF was found to predict the high RVSI (P=0.002, OR=14.134, 95% CI 2.083-71.277). CONCLUSIONS The presence of AF may affect the IRVF and cause an increase in RVSI.


Subject(s)
Atrial Fibrillation , Kidney Diseases , Humans , Atrial Fibrillation/complications , Renal Veins/diagnostic imaging , Stroke Volume , Ventricular Function, Left
4.
Turk Kardiyol Dern Ars ; 51(5): 343-348, 2023 07.
Article in English | MEDLINE | ID: mdl-37450448

ABSTRACT

OBJECTIVE: The current study investigated the contribution of the dissertations produced in the field of cardiology to the scientific literature and the factors affecting the publication process. METHODS: The study included 1049 cardiology dissertations archived in the national thesis center database between January 2010 and December 2017. The titles (English and Turkish), abstracts, and author names of cardiology dissertations were searched in Google Academic, TR Directory, and PubMed Central databases. In addition to their publication rates, the subject of the cardiology dissertations, the type of research, the type of institution, the academic title of the cardiology dissertation advisors, the duration of publication, the index of the published journals, and the quartile ranking of the Science Citation Index and Science Citation Index Expanded journals were examined. RESULTS: Among the reviewed 1049 cardiology dissertations 42.7% (n = 448) were published in a journal. The publication rate of cardiology dissertations among male authors was 43.5% and among female authors 40.1%. The cardiology dissertations were published at the highest rate after the 60th month. Among the published cardiology dissertations, 63.4% (n = 284) appeared in journals indexed by the Science Citation Index and Science Citation Index Expanded. There was no statistically significant relationship between the academic titles of cardiology dissertation advisors and the quartile ranking of Science Citation Index and Science Citation Index Expanded journals (P = 0.072). CONCLUSIONS: There were difficulties in transforming into a publication of dissertations in the field of cardiology to gain an academic identity. Incentives should be created to increase the desire and motivation of the residents.


Subject(s)
Cardiology , Publishing , Female , Male , Humans
5.
Medicina (Kaunas) ; 59(6)2023 Jun 12.
Article in English | MEDLINE | ID: mdl-37374331

ABSTRACT

Background and Objectives: Smokeless tobacco (ST) use has recently become an alternative to cigarettes, and it has been concluded that ST is at least as harmful as cigarettes. ST use is thought to play a role in the pathogenesis of arrhythmia by affecting ventricular repolarization. In this study, we aimed to examine the relationships of Maras powder (MP), one of the ST varieties, with epicardial fat thickness and new ventricular repolarization parameters, which have not previously been described. Materials and Methods: A total of 289 male individuals were included in this study between April 2022 and December 2022. Three groups, 97 MP users, 97 smokers, and 95 healthy (non-tobacco), were compared according to electrocardiographic and echocardiographic data. Electrocardiograms (ECG) were evaluated with a magnifying glass by two expert cardiologists at a speed of 50 m/s. Epicardial fat thickness (EFT) was measured by echocardiography in the parasternal short- and long-axis images. A model was created with variables that could affect epicardial fat thickness. Results: There were no differences between the groups regarding body mass index (p = 0.672) and age (p = 0.306). The low-density lipoprotein value was higher in the MP user group (p = 0.003). The QT interval was similar between groups. Tp-e (p = 0.022), cTp-e (p = 0.013), Tp-e/QT (p =0.005), and Tp-e/cQT (p = 0.012) were higher in the MP user group. While the Tp-e/QT ratio did not affect EFT, MP predicted the epicardial fat thickness (p < 0.001, B = 0.522, 95%CI 0.272-0.773). Conclusions: Maras powder may play a role in ventricular arrhythmia by affecting EFT and causing an increase in the Tp-e interval.


Subject(s)
Tobacco, Smokeless , Humans , Male , Tobacco, Smokeless/adverse effects , Powders , Echocardiography , Electrocardiography , Arrhythmias, Cardiac/etiology
7.
Anatol J Cardiol ; 26(11): 832-840, 2022 11.
Article in English | MEDLINE | ID: mdl-35949125

ABSTRACT

BACKGROUND: Cardiac autonomic neuropathy is a frequent complication of type 2 diabetes mellitus. Cardiac autonomic neuropathy, in which sympathetic tone predominates over parasympathetic activity, increases both cardiovascular morbidity and mortality and unfortunately has no definitive treatment. Sodium-glucose cotransporter-2 inhibitors have been suggested to reduce sympathetic nervous system activity, based on the results from previous studies. In this study, we aimed to investigate the effect of 24-week treatment with dapagliflozin, a sodium-glucose cotransporter-2 inhibitor, on cardiac autonomic function measures in patients with type 2 diabetes mellitus and cardiac autonomic neuropathy. METHODS: Dapagliflozin 10 mg/day (n=42) or non-sodium-glucose cotransporter-2 inhibitor oral antidiabetic(s) (n=38) was added to the treatment of patients whose glycemic control could not be achieved with existing treatments. The patients with definite or confirmed cardiac autonomic neuropathy diagnosed by cardiovascular autonomic reflex tests underwent 24-hour Holter-electrocardiogram recordings to obtain heart rate variability and heart rate turbulence parameters before starting additional medication and after a 24-week treatment period. RESULTS: In-group analyses showed that dapagliflozin 10 mg/day for 24 weeks improved heart rate variability and heart rate turbulence parameters and decreased the frequency of ventricular premature beats relative to their baseline values. No such findings were observed in the control group despite similar glycemic control. Comparisons between dapagliflozin group and the control group showed that these effects of dapagliflozin were significantly better than non-sodium-glucose cotransporter-2 inhibitor oral antidiabetics. CONCLUSION: Dapagliflozin improves measures of cardiac autonomic function compared to the control group in type 2 diabetic patients with cardiac autonomic neuropathy. This intergroup benefit, demonstrated for the first time, may be promising for the regression of cardiac autonomic neuropathy with sodium-glucose cotransporter-2 inhibitors.


Subject(s)
Diabetes Mellitus, Type 2 , Sodium-Glucose Transporter 2 Inhibitors , Humans , Diabetes Mellitus, Type 2/complications , Diabetes Mellitus, Type 2/drug therapy , Diabetes Mellitus, Type 2/diagnosis , Sodium-Glucose Transporter 2 Inhibitors/therapeutic use , Sodium-Glucose Transporter 2 Inhibitors/pharmacology , Glucosides/therapeutic use , Glucosides/pharmacology , Hypoglycemic Agents/therapeutic use , Glucose/therapeutic use
8.
Scand J Clin Lab Invest ; 80(4): 277-281, 2020 Jul.
Article in English | MEDLINE | ID: mdl-32077762

ABSTRACT

Environmental, genetic, oxidative and biochemical factors play an important role in the atherosclerotic process. We investigated the association of serum fibroblast growth factor (FGF-23), klotho, fetuin-A, osteoprotegerin (OPG), osteopontin (OPN) and high-sensitive-CRP (Hs-CRP) markers with coronary artery disease and whether one was superior to others or not. A study group of 52 patients with coronary artery disease (CAD) and a control group of 30 patients with angiographically normal epicardial coronary arteries were included in the study. Serum FGF-23, klotho, fetuin-A, OPN, OPG and Hs-CRP marker levels were studied. Patients with CAD were classified in two groups as low (SYNTAX ≤22, n = 29) and moderate-high (SYNTAX ≥ 23, n = 23) according to anatomic SYNTAX score. FGF-23 (p = .033), klotho (p < .001), fetuin-A (p = .005) and OPG (p = .001) serum marker levels were significantly lower in CAD patients than the control group. Serum levels of FGF-23 (p = .012), klotho (p = .001), fetuin-A (p = .015) and OPG (p = 0.002) were significantly different between SYNTAX tertiles and control group. Klotho (p = .025, odd ratio (OR) = 0.542, 95% confidence interval (CI): 0.317-0.926) and HT (p = .004, OR = 34.598, 95%CI:1.054-1135.657) were the independent predictors of CAD presence. Serum klotho levels of 91.48 pmol/L predicts the presence of CAD with 60% sensitivity and 96.55% specificity (p < .001, area under curve = 0.864, 95% CI = 0.768, 0.931). We found that serum klotho level is an independent predictor of presence, extent and severity of CAD.


Subject(s)
Coronary Artery Disease/blood , Coronary Artery Disease/diagnostic imaging , Glucuronidase/blood , Aged , Biomarkers/blood , C-Reactive Protein/genetics , C-Reactive Protein/metabolism , Case-Control Studies , Coronary Angiography , Coronary Artery Disease/genetics , Coronary Artery Disease/pathology , Female , Fibroblast Growth Factor-23 , Fibroblast Growth Factors/blood , Fibroblast Growth Factors/genetics , Gene Expression , Glucuronidase/genetics , Humans , Klotho Proteins , Male , Middle Aged , Osteopontin/blood , Osteopontin/genetics , Osteoprotegerin/blood , Osteoprotegerin/genetics , Prospective Studies , Severity of Illness Index , alpha-2-HS-Glycoprotein/genetics , alpha-2-HS-Glycoprotein/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...